19,109,149 20,000,956
Shengtai Pharmaceutical, Inc.
Consolidated Balance Sheets
As of December 31, 2008 and June 30, 2008
ASSETS
December 31, June 30,
2008 2008
(Unaudited)
CURRENT ASSETS:
Cash $6,881,595 $3,405,606
Restricted cash 6,319,465 6,763,500
Accounts receivable, net of allowance for
doubtful accounts of $493,507 and $440,701
as of December 31, 2008
and June 30, 2008, respectively 6,192,651 7,614,236
Notes receivable 703,206 458,630
Other receivables 175,554 691,215
Inventories 6,773,059 5,039,278
Prepayments 217,503 310,381
Loan to related party 440,100 --
Total current assets 27,703,133 24,282,846
PLANT AND EQUIPMENT, net 70,803,112 69,943,021
OTHER ASSETS:
Investment in Changle Shengshi Redian Co.,
Ltd. 3,665,602 3,607,912
Loan to related party - noncurrent -- 437,700
Intangible assets - land use right, net of
accumulated amortization 3,032,706 3,042,183
Total other assets 6,698,308 7,087,795
Total assets $105,204,553 $101,313,662
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable
'/>"/>SOURCE Shengtai Pharmaceutical, Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 Related biology technology :1.
Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 20082.
Shengtai Pharmaceutical, Inc. Appoints New CFO3.
Shengtai Pharmaceutical Retains Grayling Global As Investor Relations Counsel4.
Shengtai Pharmaceutical Completes Factory Improvements Resulting in Operational and Environmental Benefits5.
Shengtai Pharmaceutical Schedules 2009 First Quarter Financial Results and Conference Call6.
DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board7.
Mindray to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference8.
Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference9.
Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation10.
Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference11.
Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products